Forxiga (dapagliflozin) from AstraZeneca. has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with… read more.
Good cardiorespiratory fitness when young is associated with up to a 40% lower risk of developing 9 specific cancers later on—at least in men—suggests a large long term… read more.
A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in… read more.
An analysis of electronic medical records for more than 45,000 people found that COVID-19 infection was significantly associated with the development of high blood pressure, according to new… read more.
Recreational drug use may be a factor in a significant proportion of admissions to cardiac intensive care, with various substances detected in 1 in 10 such patients, suggest… read more.
The first implant in Europe of Biotroniks latest pacemaker and CRT-P generation was conducted in early August by Prof. Dr. Jan De Pooter at the University Hospital Ghent… read more.
A new study from the University of Chicago Medicine reveals that nearly 75 percent of acute stroke patients wait more than two hours to be transferred to a comprehensive stroke… read more.
Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine recently conducted a large-scale analysis to assess the impact of a newly introduced equation used to evaluate… read more.
Boston Scientific Corporation announced it has received FDA approval for the POLARx Cryoablation System.The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation… read more.
Abbott is initiating a US market withdrawal for the Trifecta family of valves and will be removing the limited remaining inventory from the field. On February 27, 2023,… read more.
Adjunctive therapy with atorvastatin appears to reduce the proportion of patients with lymphoma who are being treated with anthracyclines and who also develop cardiac dysfunction. The findings were… read more.
The FDA has identified a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.;Recalled Product Product Names: Cobalt… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
